Adenosine Deaminase Activity in Iraqi Patients with Myocardial Infarction


  • Shatha Abdul Wadood Department of Chemistry, College of Science, University of Baghdad
  • Shaema Saadon Fadel Department of Chemistry, College of Science, University of Baghdad Baghdad


Adenosine deaminase, Aspartate aminotransferase, Lipid profile, Myocardial Infarction, Biochemical marker


Adenosine deaminase (ADA) activity increases during antigenic and mitogenic responses of lymphocytes; therefore it is considered as an important immunoenzyme marker for assessing cell mediated immunity in diseases characterized by T lymphocyte proliferation and maturation. Myocardial Infarction (MI) is a term used to describe acute necrotic changes in the myocardium due to sudden deprivation of coronary blood supply. Since a relationship exists between adenosine deaminase and cell mediated immunity we have undertaken a preliminary study to determine its activity and highlight its importance in the immunopathogenesis of MI, also searching for a new biochemical marker.

METHODS: 25 cases all diagnosed with MI at admission to AL-Yarmook Hospital /Iraq. The control group consisted of 25 age and sex matched normal healthy individuals. Serum biochemical parameters were estimated by spectrometric methods such as: ADA activity, Aspartate aminotransferase (AST), lipid profile, and total protein. Statistical analysis was made by SPSS version 15 and student T- Test was used. P< 0.05 was considered significant.

RESULTS: There were significant differences (p< 0.05) in ADA levels (43.14 ± 10.8U/L) in patients than controls (20.71 ± 3.54U/L). Significant increase (p<0.05) were found in AST activity, total cholesterol, TG, and LDL-C, while level HDL-C show a significant decrease (p<0.05).

CONCLUSIONS: ADA levels may be increased to compensate the increase in adenosine levels due to MI. Also the observations of the study provide evidence for T lymphocyte activation and proliferation in MI.

GENERAL SIGNIFICANCE: We suggest that ADA may be one of the markers to elucidate the pathogenesis of MI, and may be used as drugs target.




World Health Organization (2008). The Global Burden of Disease: 2004 Update. Geneva: World Health Organization.

Chesebro JH, Rauch U, Fuster V, Badimon JJ. “Pathogenesis of thrombosis in coronary artery disease†Haemostasis, 1997, vol. 2, pp.12-18.

Reuter H, Burgess LJ, Carstens ME, Doubell AF “Adenosine deaminase activity – more than a diagnostic tool in tuberculous pericarditisâ€, Cardiovasc J South Afr; 2005, vol. 16, no. 3, pp.143–147.

Franco R, Valenzuela A, Lluis C, Blanco J. “Enzymatic and extra-enzymatic role of ecto-adenosine deaminase in lymphocytesâ€. Immunol Rev. 1998, vol. 161, pp. 27-42.

de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, and et al. “Association of Troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general populationâ€. J Am Med Assoc. 2010, vol. 304, pp. 2503 – 2512.

Giuseppe Lippi, Mario Plebani, Salvatore Di Somma, Valter Monzani, Marco Tubaro, and et al. “Considerations for early acute myocardial infarction rule-out for emergency department chest pain patients: the case of copeptin†Clin. Chem. Lab. Med. 2012, vol. 50, no.2, pp. 243–253.

Giusti G, Galanti B, Colorimetric Method. Adenosine deaminase. Bergmeyer HU, (ed). Methods of enzymatic Analysis, 3rd ed. Weinheim: Verlag chemie,; 315-323, 1984.

Lowry O.H., Rosebrough N.J., Farr A.I., Randall R.J. “Protein measurement with the Folin phenol reagent†J. Biol. Chem. 1951, vol. 193. pp. 265-275.

Haruyo Yamashita, Kazunori Shimada, Eriko Seki, Hiroshi Mokuno, Hiroyuki Daida,. “Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris†The American Journal of Cardiology2003 vol. 91, no, 2, pp. 133–136.

Yoneyama Y, Sawar, Suzuki, Miura A, Kobayashi H, Doi D, and et al. “Relation between adenosine deaminase activities and cytokines producing T cells in women with preeclampsiaâ€. Clin Biochem. 2002, vol. 335, pp. 303-306.

Jyothy.A, Surekha Rani H, Dayasagar Rao.V, Reddy PP. “Serum adenosine deaminase activity in Myocardial Infarction†Int J Hum Genet. 2003, vol. 3, no.1, pp. 65-67.

Surekha Rani H, Dayasagar Rao V, Shiva Prakash M, Jyothy A. “Serum Adenosine deaminase activity and C-reactive protein levels in unstable angina†Ind J Hum Genet, 2003, vol.9, no.1, pp.17-20.

Neela Patil, Vishwas Chavan, N.D.Karnik, Antioxidant status in patients with acute myocardial, Indian Journal of Clinical Biochemistry, 2007, vol 22. no. 1, pp.45-51.

Sharma SK, Suresh V, Mohan A., Kaur P, Saha P, Kumar A, Pande JN. “A prospective study of sensitivity and specificity of adenosine deaminase estimation in the diagnosis of tuberculosis pleural effusionâ€. Indian J Chest Dis Allied Sci. 2001, vol.43, pp.149-155.

Mishra OP, Rajiv G, Ali Z, Usha “Adenosine deaminase activity in nephrotic syndromeâ€. J Trop Pediatr; 1997, vol.43, pp.33-37.

Kose K,Yazici C, Asciglu O “The Evaluation of lipid peroxidation and adenosine deaminase activity in patients with Behcet's disease†Clin Biochem. 2001, vol. 34, pp.125-129.

Ungerer JPG,Oostuizen HM, Bissbort SH, Vermaak WJH “Serum adenosine deaminase: isoenzyme and diagnostic application†Clin Chem. 1992, vol. 38, pp.1322-1326.

Shiva M Prakash, Chennaiah S, Murthy YSR, Anjaiah E, Ananda Rao S, Suresh C “Altered Adenosine Deaminase Activity in Type 2 Diabetes Mellitusâ€. Journal Indian Academy of Clinical Medicine 2006, vol. 7, no.2, pp.34-39.

Sullivan JL, Oxborne WRA, Wedgewood RJ “Adenosine deaminase activity in lymphocytesâ€. Br J Haematol. 1977, vol. 37, pp. 157-158.

Hovi T, Smyth JF, Allison AC, Williams SC “Role of adenosine deaminase in lymphocyte proliferationâ€. Clin Exp Immunol. 1976, vol. 23, pp.395-403.

Chang FY, Shaio MF “Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitusâ€. Diabetes Res Clin Pract. 1995, vol. 28, pp.137-146.

Cave AC, Ingwall JS, Friedrich J, Liao R, Saupe KW, Apstein CS, and et al. “ATP synthesis during low-flow ischemia: Influence of increased glycolytic substrateâ€. Circulation 2000, vol. 101, pp. 2090-2096.

Brichman ,A.S.,Coburn, J.W, Massry, S.G.“Adenosine Deaminase activity in tuberculosis pleural effusions, Amarican journal of Medicine 1974, vol. 57, pp.156-161.

Ralevic V and Burnstock G “Receptors for purines and pyrimidinesâ€. Pharmacol Rev. 1998, vol.50, pp.413–492.

Kuno M, Seki N, Tsujimoto S, Nakanishi I, Kinoshita T, and et al. “Anti-inflammatory activity of non-nucleoside adenosine deaminase inhibitor FR234938â€. Eur J Pharmacol. 2006, vol. 534, pp. 241–249.

Siegmund B, Rieder F, Albrich S, Wolf K, Bidlingmaier C, and et al. “Adenosine kinase inhibitor GP 515 improves experimental colitis in miceâ€. J Pharmacol Exp Ther. 2001, vol. 296, pp. 99–105.

Hasko Ì G and Cronstein BN “Adenosine: an endogenous regulator of innate immunityâ€. Trends Immunol. 2004, vol. 25, pp.33–39.

Naganuma M, Wiznerowicz EB, Lappas CM, Linden J, Worthington MT, Ernst PB “Cutting edge: critical role for A 2a adenosine receptors in the T cell-mediated regulation of colitisâ€. J Immunol. 2006, vol. 177, pp. 2765–2769.

Riksen NP, Rongen GA, Yellon D, Smits P “Human in vivo research on the vascular effects of adenosineâ€. Eur J Pharmacol. 2008, vol.13, pp.220-222.

Eigler A, Matschke V, Hartmann G, Erhardt S, Boyle D, Firestein GS, Endres S “Suppression of TNF-alpha production in human mononuclear cells by an adenosine kinase inhibitorâ€. J Leukoc Biol. 2000, vol. 68, pp.97–103.

Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, and et al. “Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26â€. Blood 2006, vol.108, pp.1602-1610.

Kaul A, Chandra M, Misra MK. “Adenosine deaminase in ischemia reperfusion injury in patients with myocardial infarction. J Enz Inhib Med Chem 2006, vol. 21, pp. 543-546.

Kaul A, Sethi R, Misra MK. “ Evaluation of the roles of adenosine deaminase and xanthine oxidase in reperfusion injury in patients with myocardial infarctionâ€. Clin Chim Acta 2007, vol. 380, pp. 225-227.

Sawynok J, Liu XJ. “Adenosine in the spinal cord and periphery: release and regulation of pain†Prog Neurobiol 2003, vol. 69, pp. 313-340.

Adanin S, Yalovetskiy IV, Nardulli BA, Sam AD , Jonjev ZS, and “Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis. Am J Physiol Regul Integr Comp Physiol2002, vol.282, pp. R1324-1332.

Mabley JG, Pacher P, Liaudet L, Soriano FG, Hasko Ì G,and “Inosine reduces inflammation and improves survival in a murine model of colitisâ€. Am J Physiol. 2003b, vol. 284, pp.138–144.

Hasko Ì G, Kuhel DG, Ne Ìmeth ZH, Mabley JG, Stachlewitz RF, and et al. “Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shockâ€. J Immunol. 2000, vol. 164, pp.1013–1019.

Kuddusi Erkiliç, Cem Evereklioglu, Mustafa Çekmen, Abdullah Özkiris, Fuat Duygulu, Hakki Dogan, “Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations†Mediators of Inflammation, 2003, vol.12, no.2, pp. 107-116.

Torrellas, Yulan, Ramos Belkis, Useche Antonio Franco, Pérez-Aguilar Mary Carmen, and “Increased adenosine deaminase serum activity in patients with acute myocardial infarction†Revista Latinoamericana de Hipertensión 2010, Vol. 5, no. 2, pp. 38-42.




How to Cite

Abdul Wadood, S., & Fadel, S. S. (2014). Adenosine Deaminase Activity in Iraqi Patients with Myocardial Infarction. Asian Journal of Pharmacy, Nursing and Medical Sciences, 2(1). Retrieved from